PTH
Invesco Dorsey Wright Healthcare Momentum ETF
The Invesco DWA Healthcare Momentum Portfolio tracks an index of U.S. healthcare firms selected and weighted by price momentum.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 134.4 M
ASSETS UNDER MGMT
60 bp
EXPENSES
Fund Basics
| Inception date | Oct 12, 2006 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ROIVANT SCIENCES LTD. | 5.0 % |
| PRAXIS PRECISION MEDICINES INC ORDINARY | 4.4 % |
| TANGO THERAPEUTICS, INC. | 3.6 % |
| UNITED THERAPEUTICS CORP | 3.2 % |
| AXSOME THERAPEUTICS, INC. | 3.1 % |
| TENET HEALTHCARE CORP | 2.9 % |
| BRIGHTSPRING HEALTH SERVICES, INC. | 2.7 % |
| MODERNA, INC. | 2.6 % |
| LIQUIDIA TECHNOLOGIES, INC. | 2.5 % |
| SELLAS LIFE SCIENCES GROUP INC | 2.4 % |
Constituent Breakdown
| Number of holdings | 60 |
| Herfindahl-Hirschman Index | 220 |
| Wgt avg mkt cap (mns) | $12,934 |
| Large cap (>$10bn) | 36.3% |
| Mid cap ($2-10bn) | 40.2% |
| Small cap (<$2bn) | 14.7% |
| Developed mkts. | 91.2% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 83.2 % |
 |
BRITAIN | 5.0 % |
 |
IRELAND | 2.1 % |
 |
SWITZERLAND | 0.9 % |
Historical Performance
Standardized Performance (as of 06/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 20.2% | 53.7% | 17.9% | 13.8% | 1.5% | 14.9% | -- | 10.5% |
| Dividend Yield | 0.0% | 4.7% | 1.8% | 1.2% | 0.6% | 0.4% | -- | 0.3% |
| Total Returns | 20.2% | 58.4% | 19.7% | 14.9% | 2.1% | 15.3% | -- | 10.8% | Ann. Volatility | 27.3% | 24.3% | 25.9% | 25.5% | 25.6% | 27.3% | -- | 24.9% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.98 | 26% |
| MSCI EAFE | 0.77 | 25% |
| MSCI Emg Mkts | 0.42 | 16% |
Liquidity Measures
| Avg. volume (000) | 46 |
| ADV traded (mns) | $3 |
| Turnover | 2.0% |
| Avg. Bid/Ask (% of price) | 0.25% |
Technical Indicators
| 30d moving avg. (EMA) | $56.08 |
| Relative strength (RSI) | 64 |
| MACD/Signal | 2.55/2.27 |
| Bollinger Bands (Upper/Lower) | $64.22/$49.37 |
| Short interest (% of AUM) | 0.7% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PTH |
Expenses vs. PTH |
ALTAR Score™ vs. PTH |
|---|---|---|---|---|
| XBI | State Street SPDR S&P Biotech ETF | 29.6% | -25 bp | +1.0% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 23.2% | -41 bp | +1.4% |
| BBP | Virtus LifeSci Biotech Products ETF | 19.8% | +19 bp | -2.4% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 19.4% | 0 bp | +8.0% |
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 19.0% | +19 bp | +1.2% |
| IBB | iShares Biotechnology ETF | 18.9% | -15 bp | +0.6% |
| WDNA | WisdomTree BioRevolution Fund | 18.8% | -15 bp | -1.5% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 17.6% | -25 bp | +0.4% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 16.7% | 0 bp | +0.8% |
| CANC | Tema Oncology ETF | 14.5% | +15 bp | -0.7% |
Risk and Returns: PTH vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 7/19/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-1.2%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,401 funds in the US Equity category with an average
ALTAR Score™ of 5.4% and a standard deviation
of 2.1%. PTH's ALTAR Score™ is approximately -3.2 standard
deviations above the category average. This places PTH in the 1st percentile
among funds in the category.
Sell-Side Consensus
$65.23
PRICE TARGET
+9.5%
UPSIDE